Abstract
Background: Severe osteogenesis imperfect (OI) is a disorder characterized by osteopenia, frequent fractures, progressive deformities, loss of mobility, and chronic bone pain.
Objective: The main objective of this study was to compare the efficacy and safety of zolidronate with those of pamidronate on bone mineralization and fracture incidence in OI.
Methods: The study was performed at the outpatient pediatric endocrine clinic of a children hospital. 27 prepubertal children (2-11 years old) with severe OI divide randomly in two groups, treated with either zolidronate (13 patients) or pamidronate (14 patients) for 2 years. The main outcome measures were bone mineral density and fracture incidence. Secondarily, their effects on mobility and bone turnover markers (alkaline phosphatase and C- telopeptide) were compared.
Result: Zolidronate and pamidronate had the same effects on improving the bone mineral density (p< 0.001) and reducing the fracture incidence (p< 0.001). Their effects on mobility and bone turnover markers were also similar.
Conclusion: The efficacy of zolidronate and pamidronate on improving bone mineralization and reducing fracture incidence and their safety in children with severe OI are the same.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salehpour, S., Tavakoli, S. A Randomized Controlled Comparison of Zolidronate to Pamidronate Effects Upon Bone Mineralization and Fracture Incidence in Children With Severe Osteogenesis Imperfect. Pediatr Res 70 (Suppl 5), 394 (2011). https://doi.org/10.1038/pr.2011.619
Issue Date:
DOI: https://doi.org/10.1038/pr.2011.619